All News

Found 265 articles

• Acura Pharmaceuticals Announces Third Quarter 2021 Financial Results

  11/15/2021

  Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and nine months ended September 30, 2021.

• KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates

  11/10/2021

  KemPharm, Inc., a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, reported its financial results for the third quarter ended September 30, 2021.

• 

  Clinical Catch-Up: November 1-5

  11/8/2021

  The first week of November was marked by numerous clinical trial announcements. Here’s a look.

• KemPharm Announces AZSTARYS® Clinical Data to be Featured in Poster Presentation at the 2021 Virtual International Conference on ADHD

  11/5/2021

  KemPharm, Inc. today announced that research involving AZSTARYS ® will be featured in a poster presentation during the 2021 Virtual International Conference taking place November 4-6, 2021.

• KemPharm to Report Third Quarter 2021 Results

  11/3/2021

  Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, November 10, 2021, 4:30 p.m. ET

• AZSTARYS®, An Innovative ADHD Treatment Developed by KemPharm, to be Featured in a Poster Presentation at the 2021 Psych Congress

  10/27/2021

  KemPharm, Inc. today announced that research involving AZSTARYS ® is being featured in a poster presentation during the 2021 Psych Congress being held both virtually and in-person in San Antonio, Texas

• KemPharm Announces Research Involving AZSTARYS® and Serdexmethylphenidate to be Featured in Poster Presentations at Multiple Medical Conferences during ADHD Awareness Month (October)

  10/20/2021

  KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that research involving AZSTARYS® and serdexmethylphenidate (SDX), the company’s proprietary prodrug of d-methylphenidate (d-MPH), will be featured in poster presentations during multiple medical conferences being held in October (ADHD Awareness Month).

• KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market

  10/19/2021

  KemPharm, Inc. today announced that its shares of common stock have been approved for listing to The Nasdaq Global Select Market.

• KemPharm to Present at the Benzinga Healthcare Small Cap Conference

  9/27/2021

  KemPharm, Inc. today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm, will present at the Benzinga Healthcare Small Cap Conference taking place September 29-30, 2001.

• KemPharm to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

  9/23/2021

  KemPharm, Inc. today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference taking place September 27-30, 2021.

• KemPharm to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

  9/9/2021

  KemPharm, Inc.today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm, will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.

• 

  BioSpace Movers & Shakers, Aug. 20

  8/20/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• KemPharm Appoints Tamara A. Seymour to Board of Directors

  8/18/2021

  KemPharm, Inc. announced today the appointment of Tamara A. Seymour to serve on its Board of Directors and as Chair of the Audit Committee.

• Acura Pharmaceuticals Announces Second Quarter 2021 Financial Results

  8/16/2021

  Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and six months ended June 30, 2021.

• KemPharm Reports Second Quarter 2021 Financial Results

  8/12/2021

  KemPharm, Inc., a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, reported its financial results for the second quarter ended June 30, 2021.

• KemPharm to Report Second Quarter 2021 Results

  8/5/2021

  KemPharm today announced the Company will host a Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, August 12, 2021, 4:30 p.m. ET

• Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03Amendment Extends NDA Acceptance Date

  7/26/2021

  Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (“Agreement”) regarding Acura’s LIMITx™ LTX-03 product candidate with Abuse Deterrent Pharma, LLC (“AD Pharma”) to extend the FDA Acceptance Date for LTX-03 (“NDA Acceptance Date”) to February 28, 2022.

• KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.

  7/21/2021

  KemPharm, Inc. today announced the U.S. commercial launch of AZSTARYS™

• KemPharm Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement - June 18, 2021

  6/18/2021

  KemPharm, Inc. announced it has entered into agreements with certain of its holders of its existing warrants exercisable for 6,117,509 shares of its common stock, in the aggregate, pursuant to which such holders agreed to exercise their warrants for cash in exchange for the Company’s agreement to issue in a private placement new warrants to purchase up to 1,529,379 shares of its common stock.

• KemPharm Issues Letter to Shareholders

  6/16/2021

  KemPharm, Inc.today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, has issued a Letter to Shareholders in connection with the Company’s 2021 Annual Meeting of Stockholders to be held on June 17, 2021.